MicroRNA-630: A potential guardian against inflammation in diabetic kidney disease

Abstract

In this editorial, we comment on the article by Wu et al published “MicroRNA-630 alleviates inflammatory reactions in rats with diabetic kidney disease by targeting toll-like receptor 4”. Diabetic kidney disease (DKD) stands as a significant complication occurring from diabetes mellitus, which contributes substantially to the morbidity and mortality rates worldwide. Renal tubular epithelial cell da-mage, often accompanied by inflammatory responses and mesenchymal trans-differentiation, plays a pivotal role in the progression of DKD. Despite extensive research, the intricate molecular mechanisms underlying these processes remain to be determined. Wu et al remarkable work identifies microRNA-630 (miR-630) as an emerging potential regulator of cell migration, apoptosis, and autophagy, prompting investigation into its association with DKD pathogenesis. This study endeavors to elucidate the impact of miR-630 on TEC injury and the inflammatory response in DKD rats. The role of miR-630 in human DKD will be of interest for future studies.

Keywords: Diabetic kidney disease; MicroRNA; MicroRNA-630; Toll-like receptor 4; Inflammation

Core Tip: Wu et al identified microRNA-630 as a promising candidate for the management of diabetic kidney disease, exerting its protective effects through the regulation of toll-like receptor 4-mediated inflammatory pathways. Further research elucidating the precise molecular mechanisms underlying microRNA-630’s actions and its therapeutic potential is warranted, with the ultimate goal of developing targeted interventions to alleviate the burden of diabetic kidney disease and improve patient outcomes.